Alogliptin benzoate
China [CN] alogliptin benzoate, also known as alogliptin, is a serine protease dipeptidyl peptidase IV (DPP-IV) inhibitor developed by Takeda Corporation of Japan. This product can maintain the levels of glucagon-like peptide 1(GLP-1) and glucose-dependent insulin-stimulating peptide (GIP) in the body, promote the secretion of insulin, and thereby exert a hypoglycemic effect. The results of a randomized, placebo-controlled clinical trial showed that compared with placebo, agliptin monotherapy could significantly improve blood glucose control in patients with type 2 diabetes, without increasing the incidence of hypoglycemia, and had good tolerance. Agliptin and its drug composition are orally effective specific DPP-IV inhibitors following sitagliptin and vigagliptin on the market, providing a new and important treatment option for patients with type 2 diabetes and having broad application prospects. Agliptin benzoate was officially launched in China in early 2014. It is one of the first type 2 diabetes treatment drugs approved in China with proven cardiovascular safety data, which provides more and better options for the treatment of type 2 diabetes.
Click enlarge Image